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responses in aggressive breast 
cancer subgroups
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Studies indicate that stathmin expression associates with PI3K activation in breast cancer, suggesting 
stathmin as a marker for targetable patient subgroups. Here we assessed stathmin in relation to tumour 
proliferation, vascular and immune responses, BRCA1 germline status, basal-like differentiation, 
clinico-pathologic features, and survival. Immunohistochemical staining was performed on breast 
cancers from two series (cohort 1, n = 187; cohort 2, n = 198), and mass spectrometry data from 24 
cases and 12 breast cancer cell lines was examined for proteomic profiles. Open databases were also 
explored (TCGA, METABRIC, Oslo2 Landscape cohort, Cancer Cell Line Encyclopedia). High stathmin 
expression associated with tumour proliferation, p53 status, basal-like differentiation, BRCA1 
genotype, and high-grade histology. These patterns were confirmed using mRNA data. Stathmin mRNA 
further associated with tumour angiogenesis, immune responses and reduced survival. By logistic 
regression, stathmin protein independently predicted a BRCA1 genotype (OR 10.0, p = 0.015) among 
ER negative tumours. Cell line analysis (Connectivity Map) implied PI3K inhibition in tumours with high 
stathmin. Altogether, our findings indicate that stathmin might be involved in the regulation of tumour 
angiogenesis and immune responses in breast cancer, in addition to tumour proliferation. Cell data 
point to potential effects of PI3K inhibition in tumours with high stathmin expression.
Breast cancer is a heterogeneous disease with different molecular subtypes1,2. Among these, the basal-like cate-
gory represents 10–15% of all cases. Most of the basal-like tumours are triple negative (ER−/PR−/HER2−), with 
high histological grade and usually a more aggressive clinical behaviour. Importantly, basal-like and triple nega-
tive breast cancers are also heterogeneous3–5, and current studies explore novel treatment targets and improved 
markers for these breast cancer subtypes. Notably, there is a strong association between cases arising in heterozy-
gotes for pathogenic BRCA1 variants and a basal-like phenotype6. Henceforth, this genotype will be referred to 
as BRCA1 positive.
Stathmin is a microtubule destabilizing protein important for the construction and function of the mitotic 
spindle7,8. Active, non-phosphorylated stathmin depolymerizes microtubules during interphase and late mito-
sis8,9. Tight regulation of stathmin function through phosphorylation, and de-phosphorylation is necessary for 
optimal function of the mitotic spindle and orderly progression through the cell cycle9–11. In addition to its role 
in mitosis, stathmin is involved in the regulation of other cellular processes such as epithelial polarity, apopto-
sis, and cell motility12–14. Further, Segatto and colleagues recently demonstrated that stathmin is required for 
∆16HER2-driven early breast cancer development in mice14.
In breast cancer, high stathmin levels are associated with aggressive features15–17 and reduced survival17–20, 
and overexpression is reported in a variety of other human malignancies12,13,21. Regarding treatment, studies 
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indicate that stathmin expression associates with PI3K activation, suggesting that it could be a potential marker 
of targetable patient subgroups. Breast cancer cell lines overexpressing stathmin exhibits decreased sensitivity 
to paclitaxel and vinblastine22, and a combination of anti-stathmin therapy and taxol has proven more effective 
than anti-stathmin therapy alone23. In a study on locally advanced breast cancer, low stathmin levels predicted 
response to docetaxcel-containing neoadjuvant therapy24.
Although stathmin plays an important role in the regulation of cell structure and function, including pro-
liferation and hence tumour growth, little is known about its effects on the tumour microenvironment. Here, 
we examined stathmin expression in tumour cells as a potential marker of aggressive breast cancer subgroups. 
In particular, we studied the relation between stathmin and key tumour drivers such as proliferation and fea-
tures of the tumour microenvironment, like angiogenesis and immune responses. Stathmin associations with 
basal-like phenotypes and the BRCA1 positive genotype were explored at protein and mRNA levels. Finally, 
the association between stathmin and drug response patterns was mapped using cell line data, with particular 
focus on the PI3K pathway, and with the perspective of stathmin as a potential marker of targetable breast 
cancer subgroups.
Results
Stathmin expression in normal breast tissue. By immunohistochemistry, stathmin protein expression 
was mainly negative or weak in normal breast epithelial tissue. Moreover, some stathmin expression was seen 
in scattered immune cells and endothelial cells in benign breast tissue as well as in conjunction with carcino-
ma-in-situ changes.
Stathmin expression is associated with aggressive tumour features. Immunohistochemical stain-
ing of stathmin protein was mainly localised in the tumour cell cytoplasm, and was recorded as high in 60% 
(112/187) and 80% (158/198) of the cases in cohort 1 and cohort 2, respectively (Fig. 1a,b).
High stathmin expression was associated with high histological grade in both cohorts (p ≤ 0.002), tumour 
diameter > 20 mm in cohort 1 (p = 0.018), and ER (estrogen receptor) and PR (progesterone receptor) negativity 
in cohort 2 (p = 0.003 and p = 0.001; Table 1). In addition, high stathmin associated with strong p53 staining 
and a triple negative phenotype (TNP) in both cohorts (p ≤ 0.005 and p ≤ 0.012; Supplementary Tables S1–2). 
Stathmin was not associated with HER2 (human epidermal growth factor receptor 2) positivity, axillary lymph 
node status (Table 1), interval-detected tumours or locally advanced disease (data not shown).
In the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohorts, high stath-
min mRNA expression was associated with high histological grade (both p < 0.001), tumour diameter > 20 mm 
(p = 0.019; validation cohort), and ER negativity both when assessing stathmin mRNA as a dichotomised varia-
ble (p < 0.001; cut-off median; Supplementary Table S3) and as a continuous variable (p ≤ 0.038). In The Cancer 
Genome Atlas (TCGA) cohort, stathmin mRNA expression was associated with ER negativity (p < 0.001; cut-off 
upper quartile; Supplementary Table S4).
Stathmin expression is associated with a basal-like phenotype. The core basal-like phenotype 
(ER−, HER2−, CK5/6+ and/or EGFR+) was seen in 10% (19/184) and 20% (39/192) of the cases in cohort 1 and 
cohort 2, respectively. We found significant associations between high stathmin protein expression and individual 
basal-cell markers: CK5/6 (p ≤ 0.006; cohort 1–2) and P-cadherin (p = 0.021; cohort 2), but not with EGFR (epi-
dermal growth factor receptor) expression (Table 1 and Supplementary Tables S1–2). High stathmin expression 
was significantly associated with all five immunohistochemistry-based basal-like profiles (see Supplementary 
Methods) in both cohorts (OR 3.71–14.28, p ≤ 0.033; Supplementary Tables S1–2).
In multiple logistic regression analysis including stathmin, mitotic count, and p53 as explanatory variables, 
high mitotic count (p = 0.025) and strong p53 staining (p < 0.001) were significant and independent predictors 
of the core basal phenotype in cohort 1, whereas stathmin (p = 0.040) was of borderline significance (Table 2). 
When using Ki67 as a proliferation marker and including histological grade in the model, only high Ki67 count 
(p = 0.003) and strong p53 staining (p = 0.002) were significant (Supplementary Table S5). In cohort 2, high 
stathmin expression (p = 0.001) and high p53 levels (p = 0.003) significantly and independently predicted the 
core basal phenotype, whereas mitotic count was not significant (Table 2).
High stathmin mRNA expression was strongly associated with the basal-like subtype in TCGA and the 
two METABRIC cohorts (all p < 0.001; Fig. 1c; Supplementary Tables S3–4). In the breast cancer cell lines of 
the Cancer Cell Line Encyclopedia25, high stathmin mRNA associated with a basal-like phenotype (p = 0.023; 
Fig. 1d). Further, stathmin mRNA significantly correlated with the luminal progenitor signature score and 
was negatively correlated with the mature luminal signature score presented by Lim et al.26; (both p < 0.001; 
Supplementary Fig. S1a,b).
We found a significant association between high stathmin protein expression and positivity for the candidate 
stem cell marker nestin by immunohistochemistry (IHC) (both cohorts; p ≤ 0.003; Supplementary Tables S1–2). 
Further, stathmin mRNA correlated with a nestin signature27, reflecting basal-like and stemness features 
(p < 0.001; Supplementary Fig. S1c).
Proteomic analyses showed higher abundance of stathmin in basal-like compared to luminal-like breast can-
cer samples, in both in-house cell line data (n = 12; fold change = 1.8, p = 0.004; Fig. 1e) and in-house patient 
samples (n = 24; fold change = 4.4, p = 0.007; Fig. 1f). These results were validated by external data from the 
CPTAC TCGA Cancer Proteome Study of Breast Tissue28 and the Oslo2 Landscape cohort29, where both showed 
increased stathmin in basal-like compared to non-basal tumours (p ≤ 0.007; Fig. 1g,h). Taken together, the data 
indicate a consistent relationship between stathmin and a basal-like breast cancer phenotype.
From the list of genes differentially expressed between stathmin-high and -low tumours, we identified a 
stathmin mRNA signature composed of genes with a fold change ≤−2.0 or ≥2.0 (FDR < 0.006; 332 genes). 
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A stathmin mRNA signature score was derived (see Supplementary Methods), and a high stathmin score was 
seen in basal-like tumours (p < 0.001; Supplementary Fig. S2a,b). Moreover, strong correlations (positive and 
negative, respectively) between this stathmin score and the luminal progenitor score (p < 0.001; r(s) = 0.78), 
Figure 1. Stathmin mRNA and protein levels are significant higher in basal compared to non-basal breast cancer. 
Strong (a) and weak (b) cytoplasmic stain for stathmin protein in breast carcinoma. Stathmin mRNA expression in 
basal-like and non-basal breast cancer in the TCGA cohort (c) and the Barretina cell line data (d). Stathmin protein 
abundance in basal-like compared to luminal-like cell lines (e), and tumour cells from microdissected patient samples 
(cohort 1) (f). Stathmin protein abundance in basal-like compared to non-basal tumours from patients in the CPTAC 
TCGA Cancer Proteome Study of Breast Tissue (g) and from patients in the Oslo2 Landscape cohort (h). Data shown 
with error-bars representing 95% confidence interval of the mean, and p-values by Mann-Whitney U-test.




Stathmin low (n = 75) Stathmin high (n = 112)
OR 95% CI P-valuean (%) n (%)
Tumour diameter 0.018
≤20 mm 48 (48.0) 52 (52.0) 1
>20 mm 27 (31.0) 60 (69.0) 2.05 1.13, 3.74
Hist. grade 0.002
Grade 1–2 68 (45.6) 81 (54.4) 1
Grade 3 7 (18.4) 31 (81.6) 3.72 1.54, 8.98
Nodal statusb 0.220
Neg 42 (37.2) 71 (62.8) 1
Pos 32 (46.4) 37 (53.6) 0.68 0.37, 1.26
ER 0.083
Pos (≥10%) 63 (43.4) 82 (56.6) 1
Neg (<10%) 12 (28.6) 30 (71.4) 1.92 0.91, 4.05
PR 0.554
Pos (≥10%) 52 (41.6) 73 (58.4) 1
Neg (<10%) 23 (37.1) 39 (62.9) 1.21 0.65, 2.26
HER2c 0.725
Neg 65 (40.6) 95 (59.4) 1
Pos 10 (37.0) 17 (63.0) 1.16 0.50, 2.70
CK5/6 0.006
Neg, score = 0 70 (44.3) 88 (55.4) 1
Pos, score >0 5 (17.2) 24 (82.8) 3.82 1.39, 10.51
Mitotic countd 0.001
Low, ≤5.5 63 (47.7) 69 (52.5) 1
High, >5.5 12 (21.8) 43 (78.2) 3.27 1.58, 6.76
Ki67 counte <0.001
Low, ≤31.5% 64 (49.6) 65 (50.4) 1
High, >31.5% 11 (19.3) 46 (80.7) 4.12 1.96, 8.66
Cohort 2
Variables
Stathmin low (n = 40) Stathmin high (n = 158)
OR 95% CI P-valuea
n (%) n (%)
BRCA1 mutation 0.001
Absent 38 (25.9) 109 (74.1) 1
Present 2 (3.9) 49 (96.1) 8.54 1.98, 36.83
Tumour diameterf 0.515
≤20 mm 24 (21.8) 86 (78.2) 1
>20 mm 14 (17.9) 64 (82.1) 1.28 0.61, 2.66
Hist. gradeg <0.001
Grade 1–2 36 (36.4) 63 (63.6) 1
Grade 3 3 (3.5) 83 (96.5) 15.81 4.66, 53.68
ERh 0.003
Pos (≥10%) 28 (28.3) 71 (71.7) 1
Neg (<10%) 11 (11.5) 85 (88.5) 3.05 1.42, 6.55
PRh 0.001
Pos (≥10%) 28 (28.9) 69 (71.1) 1
Neg (<10%) 10 (10.3) 87 (89.7) 3.53 1.61, 7.77
HER2i 0.537j
Neg (0–2) 38 (21.2) 141 (78.8) 1
Pos (3) 2 (11.1) 16 (88.9) 2.16 0.48, 9.79
CK5/6k 0.004
Neg, score = 0 37 (24.7) 113 (75.3) 1
Pos, score >0 2 (4.7) 41 (95.3) 6.71 1.55, 29.11
Mitotic countd <0.001
Low (≤12.2) 38 (27.3) 101 (72.7) 1
High (>12.2) 1 (2.2) 45 (97.8) 16.93 2.25, 127.17
Table 1. Associations between stathmin protein expression and clinico-pathological and molecular 
characteristics in breast cancer. Cohort 1 (n = 187) and cohort 2 (n = 198). n: number of patients; OR: odds 
ratio; CI: confidence interval; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal 
growth factor receptor 2; CK5/6: cytokeratin 5/6. aPearson’s chi-squared test; bFive cases with missing 
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the nestin score (p < 0.001; r(s) = 0.57), and the luminal mature score (p < 0.001; r(s) = −0.84) were observed 
(Supplementary Fig. S2c–e). These data support a strong relation between stathmin, the basal-like phenotype, 
and features of stemness.
High stathmin expression associates with germline BRCA1 mutations. A core basal phenotype 
was seen in 43% (22/49) of the BRCA1 positive cases in cohort 2. High stathmin expression associated with 
BRCA1 germline mutations (OR 8.5, p = 0.001; Table 1). When adjusting for ER, mitotic count, p53 and CK5/6 
in the prediction of BRCA1 mutation status, we demonstrated a significant interaction between ER and stathmin. 
Notably, when stratifying the cohort by ER status, high stathmin expression alone predicted BRCA1 mutations 
among ER negative tumours (p = 0.002; Table 3), whereas in ER positive tumours, none of the above-mentioned 
markers could predict BRCA1 positive status. Due to few BRCA1 positive cases in the ER positive group (n = 6), 
we repeated the analyses using exact logistic regression to avoid small sample bias. The results were similar; in the 
ER negative group, only stathmin predicted BRCA1 positive status (median unbiased estimate from exact logistic 
regression: OR 10.02, p = 0.015), while in the ER positive group, none of the markers were significant. Stathmin 
alone predicted BRCA1 mutation status among ER negative tumours in a subgroup (n = 25) of patients under 40 
years (p = 0.032). Notably, in ER negative tumours that were negative for the basal-cell marker CK5/6 (n = 53), 
stathmin alone predicted BRCA1 status (p = 0.004), whereas none of the markers (stathmin, mitotic count, p53) 
could predict BRCA1 status in ER negative, CK5/6 positive tumours (n = 35).
In TCGA, high stathmin mRNA associated with BRCA1 germline mutations (OR = 3.74, p = 0.021; 
Supplementary Table S4). When adjusting for ER and TP53 mutations, stathmin did not independently predict 
BRCA1 mutations, possibly due to the few BRCA1 mutated cases (n = 13) in this cohort.
High stathmin expression associates with tumour cell proliferation. Stathmin protein levels 
showed strong and significant associations with tumour cell proliferation measured by mitotic count or Ki67 
(p ≤ 0.001; Table 1). The median mitotic count and Ki67 levels gradually increased with increasing stathmin 
staining index levels (p < 0.001, both cohorts; Supplementary Fig. S3a–c).
Mitotic count and Ki67 were significantly higher in the stathmin high compared with stathmin low group 
(p < 0.001; Fig. 2a–c and Supplementary Fig. S4a–c). Tumours with high stathmin had a median mitotic count of 3.8 
mitoses/mm2 (Ki67 25%) and 6.6 mitoses/mm2, compared with 0.8 mitoses/mm2 (Ki67 13%) and 1.3 mitoses/mm2 in 
tumours with low stathmin (cohort 1 and 2, respectively). Tumours co-expressing stathmin and p53 had an especially 
high median mitotic count of 10.1 mitoses/mm2 (Ki67 60%) and 9.2 mitoses/mm2 compared with 2.1 mitoses/mm2 
(Ki67 18%) and 3.3 mitoses/mm2 for cases without co-expression (cohort 1–2).
In multiple logistic regression analysis with stathmin, ER, p53, HER2, and CK5/6 as explanatory variables, 
stathmin expression (p = 0.024), HER2 status (p = 0.003) and p53 levels (p = 0.002) were significant and inde-
pendent predictors of proliferation by mitotic count in cohort 1 (Table 4). Stathmin (p = 0.031), histological grade 
(p = 0.001), ER (p = 0.044), HER2 (p = 0.017) and p53 levels (p = 0.012) were independent predictors of prolifer-
ation by Ki67 expression (Supplementary Table S6). In cohort 2, only high stathmin (p = 0.001) and ER negativity 
(p < 0.001) independently predicted high proliferation by mitotic count (Table 4).
When examining genes differentially expressed between stathmin-high and –low tumours, several genes 
involved in cell proliferation were among the top ranked upregulated genes (TCGA cohort; FDR < 0.006). In 
GSEA, gene sets reflecting mitosis and cell proliferation were enriched among stathmin-high cases (FDR < 0.001). 
Validating the GSEA output, high stathmin mRNA expression correlated with mRNA signatures reflecting 
tumour cell proliferation (Oncotype Dx30 and a PCNA score31; all p < 0.001; r(s) = 0.73–0.81; Fig. 2d,e).
High expression of stathmin in tumour cells associates with vascular proliferation and immune cell 
activation responses. Significant positive associations between immunohistochemically detected stathmin 
protein in tumour cells and the two angiogenesis markers proliferative microvessel density (pMVD) (both cohorts; 
p ≤ 0.047) and vascular proliferation index (VPI) (cohort 2; p = 0.007) were found (Supplementary Tables S1–2).
When exploring genes differentially enriched between stathmin-high and -low tumours, gene sets reflecting 
VEGF signalling and immune cell activation were enriched among stathmin-high cases (GSEA; FDR < 0.001). 
For validation, we demonstrated that high stathmin mRNA correlated with mRNA signatures reflecting vascu-
lar proliferation32 and VEGF signalling33 (all p < 0.001; r(s) 0.30–0.40; Fig. 3a,b), and the immune cell markers 
FOXP3, CTLA4, PD-L1, and PD-1 (all p < 0.001; Fig. 3c–f).
The stathmin signature correlated with stathmin mRNA expression (p < 0.001; Supplementary Fig. S2f) 
and strongly with two tumour cell proliferation scores (Oncotype Dx and the PCNA score; both p < 0.001; 
Supplementary Fig. S2g,h). Further, the stathmin signature correlated with a vascular proliferation score and a 
VEGF score (both p < 0.001; Supplementary Fig. S2i,j). As seen for stathmin mRNA expression, high stathmin 
signature score was associated with higher expression of the immune cell markers FOXP3, CTLA4, PD-L1 and 
PD-1 (all p < 0.001; Supplementary Fig. S2k–n).
information on nodal status; cHER2 positive cases: HER2 IHC 3+ and HER2 IHC 2+ cases with a HER2/
Chr17 ratio by SISH ≥ 2.0; dMitoses/mm2. Cut-off value by upper quartile. Thirteen cases with missing 
information on mitotic count in cohort 2; eCut-off value by upper quartile. One case with missing information 
on Ki67 count; fTen cases with missing information on tumour diameter; gThirteen cases with missing 
information on histological grade; hThree and four cases with missing information on ER and PR status; 
iImmunohistochemistry only. One case with missing information on HER2 status; jFisher’s exact test; kFive cases 
6Scientific RepoRtS |         (2020) 10:2914  | https://doi.org/10.1038/s41598-020-59728-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Notably, the stathmin mRNA signature score correlated stronger with tumour cell proliferation, vascular pro-
liferation, stemness, and immune cell activation compared with stathmin mRNA expression.
Using the breast cancer cell lines of the Cancer Cell Line Encyclopedia (CCLE), the stathmin mRNA signature 
score was significantly associated with our vascular proliferation score, VEGF expression, hypoxia scores (Hu 
2009 and Halle 2012)34,35, PD-L1 expression and the nestin mRNA signature score (all p < 0.001; Supplementary 
Fig. S5a–f). Thus, associations between the stathmin signature score and vascular markers, hypoxia scores and 
PD-L1 expression as well as the nestin signature score was also evident at the tumour cell level in the CCLE data, 
and support the results from our in-house patient cohorts and the TCGA cohort.
High stathmin mRNA expression associates with reduced survival. Stathmin protein expression by 
IHC was not significantly associated with breast cancer specific survival (univariate analysis; cohort 1).
In METABRIC cohorts, high stathmin mRNA associated with shorter disease specific survival, both when 
assessed as a continuous variable (both cohorts: HR 1.5; 95% CI 1.3–1.8, p < 0.001) and when dichotomised 
(discovery cohort: HR 1.4; 95% CI 1.4–2.4, p < 0.001; validation cohort: HR 2.0; 95% CI 1.5–2.7, p < 0.001; 
Fig. 4). Stathmin mRNA expression also predicted outcome in the datasets of the “KM plotter” database36 
(Supplementary Fig. S6). In multivariate survival analyses (METABRIC cohorts), adjusting for tumour size, his-
tological grade and lymph node status, high stathmin mRNA expression independently associated with shorter 
disease specific survival (discovery cohort: HR = 1.6, 95% CI 1.2–2.1; p = 0.001; validation cohort: HR = 1.7, 95% 
CI 1.3–2.3; p < 0.001). In addition, when also adjusting for molecular subtypes, stathmin maintained its prog-
nostic information with borderline significance in the discovery cohort (HR = 1.4, 95% CI 0.99–1.3; p = 0.057).
Compounds with potential PI3K inhibitory properties in tumours with high stathmin. We 
queried the drug signature database Connectivity Map37 (version 02) for drug-effect gene expression profiles 
anti-correlated to genes differentially expressed between high and low stathmin mRNA expression. Among 1309 
small molecules represented in Connectivity Map, expression profiles from compounds with PI3K inhibitory 
properties were top ranked (TCGA; Supplementary Table 7). These compounds might have a potential to drive 
stathmin-high tumours into a stathmin-low state, with less aggressive phenotype, proposing a potential relevance 
for PI3K inhibitors in stathmin-high tumours.
Discussion
Stathmin is a known regulator of the mitotic spindle and hence cellular proliferation. In relation to breast cancer, 
stathmin has been associated with aggressive features such as large tumour size15, high histological grade15,16, 
hormone receptor negativity15–17,20, basal-like and triple negative phenotypes17, as well as reduced survival in 
some studies18–20,38. Here, we show for the first time that stathmin protein expression by IHC is strongly related 
to BRCA1 positive breast cancers. The finding is further supported by our data that stathmin mRNA is associated 
with BRCA1 positive status in the TCGA-cohort, in line with one small mRNA-based study by Bane et al.39. In a 
Cohort 1 Unadjusted model Adjusted model, n = 184
Variables n OR 95% CI P-value OR 95% CI P-value
Mitotic counta <0.001 0.025
Low, ≤5.5 129 1 1
High, >5.5 55 11.72 3.68, 37.34 4.26 1.16, 15.69
p53 <0.001 <0.001
Low, score ≤3 152 1 1
High, score >3 32 22.87 7.37, 70.95 10.70 3.14, 36.39
Stathmin <0.001 0.040
Low, score ≤4 74 1 1
High, score >4 110 14.28 1.86, 109.51 6.41 0.75, 54.68
Cohort 2 Unadjusted model Adjusted model, n = 179
Variables n OR 95% CI P-value OR 95% CI P-value
Mitotic counta 0.005 0.191
Low, ≤12.2 134 1 1
High, >12.2 46 3.04 1.41, 6.57 1.74 0.76, 3.96
p53 <0.001 0.003
Low, score ≤3 137 1 1
High, score >3 54 5.61 2.65, 11.88 3.37 1.51, 7.52
Stathmin <0.001 0.001
Low, score ≤4 38 1 1
High, score >4 154 —b — —b —
Table 2. Prediction of the core basal phenotype (ER−, HER2−, CK5/6+ and/or EGFR+) by logistic regression. 
Cohort 1 (n = 187) and cohort 2 (n = 198). n: number of cases; OR: odds ratio; CI; confidence interval. aMitoses/
mm2, cut-off value by upper quartile; bOdds ratio could not be calculated due to zero BLP4 positive cases in the 
stathmin low group.
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multivariate prediction model, we show that stathmin protein assessed by IHC is independently associated with 
BRCA1 status among ER negative tumours. In this model, the basal-like phenotype, by CK5/6 expression, was 
not significant. Larger studies are needed to elucidate the predictive value of stathmin among ER positive cases.
It has been suggested that stathmin expression segregates with features of less differentiated tumours with 
stem cell characteristics17. This is supported by our results, showing significant associations between stathmin 
and the stemness marker nestin, which is reported to be strongly associated with BRCA1 positive status, basal-like 
Cohort 2 Adjusted model, n = 87
Variables OR 95% CI P-value
Mitotic count 0.543
Low, ≤12.2 1
High, >12.2 1.33 0.53, 3.33
p53 0.228
Low score, ≤3 1
High score, >3 1.78 0.70, 4.56
CK5/6 0.684
Neg, score = 0 1
Pos, score >0 1.22 0.47, 3.13
Stathmin 0.002
Low score, ≤4 1
High score, >4 —a —
Table 3. Prediction of BRCA1 germline mutation status among ER negative tumours by multiple logistic 
regression. Cohort 2 (n = 198). n: number of cases; OR: odds ratio; CI: confidence interval, CK5/6: cytokeratin 
5/6. aOdds ratio could not be calculated due to zero stathmin low cases in the BRCA1 positive group.
Figure 2. High stathmin associates with proliferation. Tumour cell proliferation by mitotic count, MC (a,b) and 
Ki67 (c) in stathmin low and high groups (by IHC) in breast cancers from the two patient cohorts. Correlation 
between stathmin mRNA expression, the Oncotype DX proliferation signature (d) and PCNA signature score 
(e) in the TCGA cohort. Data shown with error-bars representing 95% confidence interval of the mean, and 
p-values by Mann-Whitney U-test. Scatter plots are presented with p-values by Spearman’s rank correlation and 
the coefficients (ρ).
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phenotypes, and reduced survival27. We also found strong associations between stathmin and basal-like breast 
cancer profiles present in two in-house patient cohorts, in proteomics data from our own as well as external 
cohorts, from cell line studies, and in public mRNA data.
As predicted, our results point to strong associations between stathmin protein and markers of tumour cell 
proliferation in breast cancer such as Ki67 expression and mitotic count. Notably, stathmin protein showed an 
independent value among other markers in prediction of tumour proliferation. Similar findings were found at 
the mRNA level, where associations with proliferation related gene signatures such as Oncotype Dx and the 
PCNA score were seen. Results from a study by Miceli and colleagues supports that stathmin leads to increased 
proliferation in vitro and tumour growth in vivo. First, they showed that adenovirus-mediated delivery of an 
anti-stathmin ribozyme gene into breast cancer cell lines decreased proliferation irrespective of the ER status. 
Next, they demonstrated reduced growth of mammary tumours in nude mice after anti-stathmin therapy23. In 
a clinical study on lapatinib, a decrease in stathmin level was associated with Ki67 reduction in HER2 negative 
breast cancer. Pre-treatment levels of stathmin were, however, not predictive of response to lapatinib treatment40.
She and colleagues recently reported that stathmin protein expression was significantly higher in tumours with 
PTEN protein loss, as well as in tumours expressing a PTEN loss gene expression signature41. Stathmin has previously 
been suggested as a protein marker for PTEN loss and is therefore suggested as a useful test for PI3K pathway activa-
tion18. PI3K inhibitors as monotherapy in breast cancer, including in triple negative cancer, have so far not demon-
strated significant efficacy in clinical trials42,43, although combinations of PI3K inhibitors with other targeted drugs have 
shown promising results, such as the combination between PI3K inhibitors and fulvestrant43,44. A combination of PI3K/
mTOR- and PARP inhibitors has been suggested to improve outcomes in breast cancer patients with BRCA germline 
mutations, a basal-like or a triple negative phenotype45–47. Notably, we found that compounds with PI3K inhibitory 
properties negatively correlated with the transcriptional pattern of stathmin-high cases (Connectivity Map analyses), 
suggesting adding PI3K inhibitors as a treatment strategy with potential relevance in stathmin-high tumours.
Cohort 1 Unadjusted model Adjusted model, n = 187
Variables n OR 95% CI P-value OR 95% CI P-value
ER <0.001 0.362
Pos, ≥10% 145 1 1
Neg, <10% 42 3.73 1.82, 7.67 1.53 0.62, 3.81
HER2a 0.002 0.003
Neg 160 1 1
Pos 27 3.75 1.62, 8.68 4.25 1.66, 10.88
p53 <0.001 0.002
Low, score ≤3 154 1 1
High, score >3 33 7.33 3.23, 16.65 4.36 1.67, 11.37
CK5/6 <0.001 0.287
Neg, score = 0 158 1 1
Pos, score >0 29 3.70 2.19, 6.25 1.74 0.64, 4.78
Stathmin 0.001 0.024
Low, score ≤4 75 1 1
High, score >4 112 3.27 1.58, 6.76 2.44 1.10, 5.41
Cohort 2 Unadjusted model Adjusted model, n = 180
Variables n OR 95% CI P-value OR 95% CI P-value
ER <0.001 <0.001
Pos, ≥10% 95 1 1
Neg, <10% 87 6.07 2.78, 13.26 4.72 1.92, 11.62
HER2b 0.056 0.585
Neg (0–2) 166 1 1
Pos (3) 18 2.72 1.00, 7.37 1.39 0.43, 4.47
p53 0.003 0.255
Low, score ≤3 131 1 1
High, score >3 51 3.00 1.48, 6.08 1.61 0.71, 3.63
CK5/6 0.069 0.576
Neg, score = 0 140 1 1
Pos, score >0 41 2.03 0.96, 4.30 0.77 0.30, 1.96
Stathmin <0.001 0.001
Low, score ≤4 39 1 1
High, score >4 146 16.93 2.25, 127.17 12.72 1.62, 99.81
Table 4. Prediction of proliferation (mitotic count) by multiple logistic regression. Cohort 1 (n = 187) and 
cohort 2 (n = 198). n: number of cases; OR: odds ratio; CI: confidence interval. aHER2 positive cases: HER2 IHC 
3+ and HER2 IHC 2+ cases with a HER2/Chr17 ratio by SISH ≥ 2.0; bImmunohistochemistry only.
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Some18–20,38, but not all16, previous studies have shown a correlation between stathmin expression and prog-
nosis in breast cancer. Here, in METABRIC cohorts, high stathmin mRNA was associated with shorter disease 
specific survival, also when adjusted for tumour size, histological grade and lymph node status. In contrast, we 
found no significant association between high stathmin protein expression and reduced breast cancer specific 
survival in our in-house series (cohort 1), perhaps due to limited sample size. A recent meta-analysis addressed 
the prognostic role of stathmin in patients with solid cancers, including breast cancer48. In tumour-type subgroup 
analysis, stathmin was associated with worse disease-free survival in breast cancer. As there were few eligible 
breast cancer studies for inclusion, the authors could not perform tumour-type subgroup analysis for overall sur-
vival or disease-specific survival. Thus, there is a need for large breast cancer studies to determine the prognostic 
role of stathmin.
Previous studies have focused mainly on the relationship between stathmin and tumour cell proliferation. 
Here, we show that stathmin expression in tumour cells might also be important for and influence processes 
Figure 3. High stathmin relates to gene expression patterns reflecting vascular proliferation and immune cell 
activation. Correlation between stathmin mRNA expression and a gene expression vascular proliferation score 
(a) and a VEGF score (b). Stathmin mRNA expression across FOXP3 (c), CTLA4 (d), PD-L1 (e) and PD-1 (f) 
mRNA quartiles. All data from the TCGA cohort. Scatter plots are presented with p-values by Spearman’s rank 
correlation and the coefficients (ρ). Data shown with error-bars representing 95% confidence interval of the 
mean, and p-values by Kruskal-Wallis test.
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in the tumour microenvironment, such as angiogenesis and immune responses, which to our knowledge is not 
well documented in breast cancer. We found that stathmin was significantly associated with VEGF and vascular 
proliferation as well as with the immune response markers FOXP3, CTLA4, PD-L1 and PD-1 in tumour tissues. 
Notably, the stathmin mRNA signature was also associated with vascular markers, hypoxia scores, and PD-L1 
expression in breast cancer cell lines. These findings might in part reflect the relationship between stathmin and 
ER negative tumours with basal-like and stemness features, since these are known for increased immune cell 
content and elevated angiogenesis49–52. Such complex interactions might be relevant for treatment possibilities 
and potential drug combination strategies.
More direct mechanistic relationships should be further explored between stathmin and tumour microen-
vironment properties. Previously, stathmin was found to control the regulation of hypoxia inducible factor 
(HIF)-1α through the PI3K/Akt/mTOR pathway in ovarian cancer cells53, and stathmin knockdown supressed 
expression of HIF-1α and vascular endothelial growth factor (VEGF) and impeded phosphorylation of riboso-
mal protein S6 kinase 1 (S6K) and Akt. Stathmin overexpression, however, upregulated expression of HIF-1α 
and VEGF53. In relation to immune responses, stathmin expression was correlated to PD-L1 levels in a study of 
head and neck squamous cell carcinoma, suggesting that there might be a relationship between stathmin and the 
immune system, and that stathmin might be associated with immune suppression54.
In conclusion, our study shows that stathmin expression is associated with several high-grade features of 
breast cancer, such as increased proliferation, ER negativity, and basal-like phenotypes. A strong and novel 
relationship between stathmin protein and BRCA1 positive ER negative cancers was found. Links between 
transcriptional patterns of high stathmin and cell line exposure data from The Connectivity Map implies that 
PI3K inhibition might be of relevance in tumours with high stathmin expression. Finally, stathmin might also 
be involved in the regulation of tumour angiogenesis and immune responses, as important co-factors in breast 
cancer progression.
Methods
Patient cohorts. The study includes 385 primary breast cancers from two independent cohorts. Cohort 
1 (n = 187), which has been previously described by our group51,55–57, is a nested case-control study based on 
the Norwegian Mammography Screening Program in Hordaland County during 1996–2001. Briefly, 95 invasive 
interval cancers were matched by tumour diameter (±2.0 mm) with 95 screen-detected cancers from a total of 
317 invasive tumours that occurred during the first two screening rounds. Three of the 190 cases were excluded 
due to different reasons. Outcome data were included from the Norwegian Cause of Death Registry (survival 
time, status, cause of death). Last date of follow-up was June 30, 2017 (median follow-up time of survivors, 222 
months; range 191–255). During follow-up, 46 patients (25%) died of breast cancer, and 40 (21%) died of other 
causes. Cohort 2 (n = 198), which has been described previously27, is a case-control study that initially included 53 
BRCA1 positive breast cancers, 45 BRCA2 positive and 53 BRCA mutation negative cases; primary breast cancers 
were collected from patients counselled at the Hereditary Cancer Clinic at the McGill University Health Centre 
(MUHC) and the Jewish General Hospital, Montreal, Canada during 1986–2005. In addition, 51 BRCA muta-
tion negative primary breast cancers from our own archive were included. The three groups were balanced with 
regards to age and size, but a strict case-by-case matching procedure could not be accomplished due to a small 
pool of available controls. Four cases lacked sufficient tumour tissue for stathmin staining and were excluded from 
the analyses. Follow-up information was not available for this cohort. The study was approved by the Institutional 
Review Board at McGill University Hospital, A03-M33-02A, and the Western Regional Committee for Medical 
and Health Research Ethics, REC West (REK 2014/1984). The informed consent was waived by the REK ethics 
committee. All studies were performed in accordance with guidelines and regulations by the University of Bergen 
and REK, and in accordance with the Declaration of Helsinki Principles.
Figure 4. Univariate breast cancer specific survival according to stathmin mRNA status. Kaplan-Meier 
univariate breast cancer specific survival analysis in the METABRIC discovery (a) and validation cohorts (b) 
according to stathmin mRNA expression (cut-point by median, log-rank test for difference). For each category, 
the number of breast cancer deaths is given, followed by the total number of cases in each category.
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Immunohistochemistry. Immunohistochemical staining for stathmin protein. In both series, stathmin 
staining was performed manually on five μm thin tissue microarray (TMA) sections from formalin-fixed and 
paraffin-embedded tumour tissue58. Whole sections were used in cases with poor quality or insufficient tumour 
material for evaluation in the TMA cores (26 cases in cohort 1, and 18 cases in cohort 2). The sections were depa-
raffinised in xylene, rehydrated through a series of graded alcohols and rinsed in distilled water. Microwave oven 
heating with Tris-EDTA, pH 9.0, at 750 W for 10 minutes followed by 350 W for 15 minutes was used for epitope 
retrieval. To reduce background staining, a peroxidase-blocking agent (DM801) and a protein block (X0909) 
were applied before the primary antibody. The TMA sections were incubated at room temperature for 60 minutes 
using a polyclonal rabbit antibody against stathmin (#3352) from Cell Signaling Technology, diluted 1:50. After 
rinsing with a wash buffer solution, EV FLEX+ Rabbit LINK (DM 805) was added for 30 minutes followed by a 
new rinsing before the EV FLEX/HPR (DM802) was used for 30 min. To add colour at the site of the target anti-
gen recognised by the primary antibody, AEC (Chromogen) K4009 was applied. Finally, sections were rinsed in 
distilled water and counterstained with Haematoxylin (S2020).
Evaluation of staining. Stathmin staining was recorded using a semi-quantitative and subjective grading sys-
tem, considering the intensity of staining (none = 0, weak = 1, moderate = 2 and strong = 3) and the proportion 
of tumour cells showing a positive reaction (<10% = 1, 10–50% = 2, >50% = 3). A staining index (values 0–9) was 
obtained as a product of staining intensity (0–3) and proportion of immunopositive cells (1–3). Stathmin expression 
was considered positive (high) for staining index ≥6 (median in cohort 1, and lower quartile in cohort 2) based on 
frequency distributions. Information on other histological variables is presented in Supplementary Methods.
Proteomics studies of laser-capture microdissected paraffin embedded tumour tis-
sue. Twenty-four formalin-fixed, paraffin-embedded (FFPE) breast cancer specimens were selected (twelve 
basal-like, six luminal A and six luminal B). All basal-like samples were also triple negative, and all luminal sam-
ples were ER and PR positive, and HER2 negative. The luminal B tumours displayed more than 15% Ki67-positive 
nuclei (whole section). All were diagnosed as invasive carcinomas (NST; previously ductal carcinomas). Ten μm 
thick FFPE sections were deparaffinised, rehydrated and stained with haematoxylin. Breast cancer epithelium 
was laser micro-dissected (PALM MicroBeam, Zeiss) and pressure catapulted into a tube cap (AdhesiveCap 500 
opaque, Zeiss). Depending on the available tissue, 0.8–1.9 × 107 µm3 were micro-dissected.
Proteomics studies of breast cancer cell lines. Basal-like breast cancer cell lines (MDA-MB-231, 
MB-468, BT-549, SUM-1315, SUM-159 and Hs 578 T) and luminal like breast cancer cell lines (MCF7, T47D, 
HCC1428, SK-Br-3, ZR-73-50 and BT-474) were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). Information on how the cell lines were cultured, and methods used for protein extraction, diges-
tion and mass spectrometry analysis is presented in Supplementary Methods.
Proteomic data analyses. Raw data from the mass spectrometer were processed using the MaxQuant 
software (v1.6.0.16) with recommended settings for label-free quantification59. Identified features were searched 
against an up-to-date human “reference proteome”-database from UniProt.org. Hands-on statistical analyses of 
processed mass spectrometry data were performed using the Perseus software (v1.6.0.7)60.
External proteomic datasets. Data from the CPTAC TCGA Cancer Proteome Study of Breast Tissue and the 
Oslo2 Landscape cohort were used for validation. The CPTAC TCGA Cancer Proteome Study of Breast Tissue 
dataset was downloaded from Clinical Proteomic Tumour Analysis Consortium (NCI/NIH), and consists of 105 
breast cancer samples, which were reduced to 77 after quality control by Mertins et al.28 18 basal-like samples, 12 
HER2 enriched, 23 luminal A and 24 luminal B. Data from the Oslo2 Landscape cohort was downloaded from 
www.breastcancerlandscape.org/. It includes 45 breast cancer samples: nine basal-like, nine HER2 enriched, nine 
luminal A, nine luminal B and nine normal breast-like samples29. The normal breast-like samples were excluded 
from analyses.
Gene expression resources. For the exploration of transcriptional patterns related to stathmin in breast 
cancer, publicly available mRNA gene expression datasets with information on clinico-pathologic and follow-up 
data and molecular subtypes were analysed. (1) The TCGA cohort (n = 505)61; (2) the METABRIC cohorts 
(discovery cohort, n = 939; validation cohort, n = 845)62. Intrinsic molecular subtypes based on PAM50 clas-
sification were available63. The normal breast-like category was excluded. Transcriptomic data from the breast 
cancer cell lines in the Cancer Cell Line Encyclopedia (n = 47 with information on molecular subtypes)25 was also 
explored. An online database, “KM plotter” (www.kmplot.com)36, including EGA (European Genome-phenome 
Archive) and GEO datasets (Affymetrix microarrays only), was used to evaluate stathmin mRNA in relation to 
recurrence-free breast cancer survival in a merged dataset of 3951 breast cancer cases. Cut-off point for analysis 
with dichotomised stathmin mRNA was defined after considering frequency distributions and survival pattern of 
quartiles (TCGA; upper quartile, METABRIC; median).
Differentially expressed genes between cases with high versus low stathmin mRNA expression were identified 
based on Significance Analysis of Microarrays (SAM)64. Gene sets significantly enriched in cases with high stath-
min mRNA expression were explored by applying the Gene Set Enrichment Analysis (GSEA; www.broadinstitute.
org/gsea)65 and the signatures of Molecular Signatures Database (MSigDB; www.broadinstitute.org/gsea/msigdb). 
Multiple probes covering the same gene were collated accordingly max probe65.
Gene expression data analyses. Details on methods applied in gene expression analysis are presented in 
Supplementary Methods.
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Statistical methods. Data were analysed using the SPSS Statistics for Windows, Version 25.0. (IBM Corp., 
Armonk, NY, USA). Statistical significance was assessed at the two-sided 5% level, whereas borderline statistical 
significance was defined as P-values between 5% and 10%. Associations between categorical variables were eval-
uated using the Pearson’s χ² test or Fisher’s exact test, as appropriate. Non-parametric correlations were tested by 
the Spearman’s rank coefficient. Continuous variables with a non-normal distribution were compared between 
two groups using the Mann-Whitney U test, and between more than two groups using Kruskal-Wallis H test. 
Multiple logistic regression analysis was utilised for prediction of BRCA1 germline mutation status, the basal-like 
phenotype and tumour cell proliferation. The calculations were done according to the Backward Elimination 
(Likelihood Ratio) method, with p-values derived from Step1 in the “model if term removed”-table. Tests for 
interactions between stathmin and selected co-variables were performed. Prediction of BRCA1 positive status 
was also performed using exact logistic regression in Stata 16 due to few BRCA1 positive cases in the ER positive 
subgroup. The end-point in survival analyses was breast cancer specific survival (BCSS) in patient cohort 1 and 
METABRIC, and recurrence-free survival (RFS) in “KM plotter”. One patient with distant metastases at time of 
diagnosis was excluded from analysis in patient cohort 1. Univariate survival analyses were carried out using the 
Kaplan-Meier method with significance determined by the log-rank test. Entry date was the date of diagnosis. 
Patients who died from other causes were censored at the date of death. Multivariate survival analyses were per-
formed on both continuous and dichotomised stathmin mRNA-data from METABRIC using Cox’ proportional 
hazards regression model. Multivariate analyses adjusted for molecular subtypes in addition to tumour diameter, 
histological grade and lymph node status. Only patients with information on all variables were included in the 
analyses.
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